Amir Goldkorn
Affiliations: | Molecular Biology | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, Cell Biology, OncologyGoogle:
"Amir Goldkorn"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Lara PN, Mayerson E, Gertz E, et al. (2024) Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Prostate Cancer and Prostatic Diseases |
| Lara PN, Mayerson E, Gertz E, et al. (2023) Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel. European Urology |
| Morris MJ, Heller G, Hillman DW, et al. (2023) Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202394 |
| Swami U, Sayegh N, Jo Y, et al. (2022) External validation of association of baseline circulating tumor cell counts with survival outcomes in men with metastatic castration-sensitive prostate cancer. Molecular Cancer Therapeutics |
| Tulpule V, Morrison GJ, Falcone M, et al. (2022) Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. Current Oncology Reports |
| Agarwal N, Tangen CM, Hussain MHA, et al. (2022) Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2102517 |
| Lu YT, Xu T, Iqbal M, et al. (2022) FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer. Cancers. 14 |
| Xu T, Junge JA, Delfarah A, et al. (2022) Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Scientific Reports. 12: 5518 |
| Morrison G, Buckley J, Ostrow D, et al. (2022) Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. International Journal of Molecular Sciences. 23 |
| Goldkorn A, Tangen CM, Plets M, et al. (2021) Baseline circulating tumor cell count as a prognostic marker of PSA response and disease progression in metastatic castrate sensitive prostate cancer (SWOG S1216). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |